Global biopharmaceutical company AbbVie has received EU approval for its $63 billion bid to acquire its rival Allergan.
Approval is conditioned on the divestment of a pipeline Allergan product for the treatment of inflammatory bowel diseases.
In announcing the approval today (see here), EU competition chief Margrethe Vestager drew